Study shows colonoscopy better than sigmoidoscopy in protecting against colorectal cancer

September 18, 2013, Massachusetts General Hospital

A study in the Sept. 19 New England Journal of Medicine finds that colonoscopy appears to reduce the risk of developing or dying from colorectal cancer more powerfully than does sigmoidoscopy, a similar procedure that examines only a portion of the colon. The investigation, which analyzes data from two long-term studies, also identifies molecular features that may help explain tumors that are diagnosed despite an individual's having recently undergone colonoscopy.

"This study provides some of the clearest evidence to date that colonoscopy has advantages over sigmoidoscopy for the prevention of colorectal , although it is not a perfect test," says Andrew Chan, MD, MPH, of the Massachusetts General Hospital (MGH) Gastrointestinal Unit, corresponding and co-senior author of the report. "Our findings support current recommendations for colorectal cancer screening with either of these procedures and provide a rationale for some individuals to consider colonoscopy as a preferred test for their individual situation."

Both colonoscopy and sigmoidoscopy allow examination of the internal surface of the colon through a fiberoptic tube with a light and camera at the end, but while colonoscopy visualizes the entire colon, sigmoidoscopy only reaches the lower third on the left side of the body. Current recommendations for colorectal screening in average-risk individuals over age 50 are either a sigmoidoscopy every 5 years – followed by colonoscopy if abnormalities are detected – or a colonoscopy every 10 years.

While randomized, controlled have confirmed that sigmoidoscopy reduces the incidence of and death from colorectal cancer, similar trials have not yet been done for colonoscopy, and some prior studies have suggested that colonoscopy did not have significant advantages over sigmoidoscopy. However, the more comprehensive colonoscopy is widely recommended for colorectal screening based on its ability to visualize the whole colon. The current study was designed to compare the effectiveness of both procedures in reducing the long-term risk of colorectal cancers in different segments of the colon and to examine molecular features of tumors developing soon after a negative examination.

To do this, the investigators analyzed information from almost 89,000 participants in the Nurses Health Study and the Health Professionals Follow-up Study, both of which gather comprehensive health information from their participants every two years. From 1988 to 2008, the participants reported whether they had either sigmoidoscopy or colonoscopy in the two preceding years and, if they had, whether the examinations were for screening purposes or because of symptoms like bleeding. For participants who developed cancer or who reported having colon polyps removed, the researchers obtained consent to review their medical records and pathology reports.

Over the 22 years for which data was analyzed, 1,815 cases of colorectal cancer and 474 related deaths were documented in the 88,902 study participants. While a negative result – meaning that neither cancer nor polyps were diagnosed – in either examination or having polyps that were removed was associated with a reduced risk of developing left-side colon cancer, only a negative colonoscopy was associated with significant risk reduction in the entire colon.

Compared with the 15 percent of study participants who had no endoscopic colon exam during the study period, having either procedure significantly reduced the overall risk of dying from colorectal cancer. But while sigmoidoscopy only cut the risk of dying from left-side tumors, screening colonoscopy reduced the risk of any colorectal-cancer-associated death.

Having a single negative colonoscopy significantly reduced the incidence of any colorectal cancer for up to 15 subsequent years, supporting the current recommendations for a 10-year interval between exams. Among participants who had polyps removed, the incidence of subsequent tumors was reduced for up to 5 years, except for those whose polyps had features indicating elevated risk, in whom the risk reduction was not as strong.

Among the participants who did develop colorectal cancer, molecular data was available on 62 tumors that had been diagnosed within 5 years after colonoscopy. The researchers identified specific cancer-related features more likely to be seen in those tumors than in cancers diagnosed after more time had passed. "It is widely believed that tumors with those features develop from a specific type of polyp called a sessile serrated adenoma, which may be particularly difficult to detect endoscopically or to remove completely," Chan explains. "Focused efforts to improve detection and removal of these polyps are a high priority.

"For individual patients, the decision to select colonoscopy over for colorectal requires discussing with their physicians how the advantages and disadvantages of each test apply to their personal situations," he adds. "Right now our data support the use of colonoscopy if the primary goal is maximum risk reduction for both left- and right-side colorectal cancers. Future study should focus on ways of further improving quality, as well as better understanding why some tumors arise within a short time after a negative examination." Chan is an associate professor of Medicine at Harvard Medical School.

Explore further: Colonoscopy screening reduces risk of advanced colorectal cancer, study finds

Related Stories

Colonoscopy screening reduces risk of advanced colorectal cancer, study finds

March 4, 2013
A new study led by the Perelman School of Medicine at the University of Pennsylvania adds support to current medical recommendations stating that screening colonoscopy substantially reduces an average-risk adult's likelihood ...

Hybrid screening strategy emerges for colorectal cancer

August 27, 2013
A strategy that combines two effective colorectal cancer screening methods, fecal immunological test and colonoscopy, may improve prevention and detection of colorectal cancer and reduce costs, according to a new study in ...

Increased use of colonoscopy screening could explain decrease in colorectal cancer rates

October 23, 2012
Use of colonoscopy for colorectal cancer screening could explain a significant decrease in the cancer's incidence over the past decade, according to a new study from researchers at the Stanford University School of Medicine. ...

Study finds sigmoidoscopy reduces colorectal cancer rates

May 21, 2012
Flexible sigmoidoscopy, a screening test for colorectal cancer that is less invasive and has fewer side effects than colonoscopy, is effective in reducing the rates of new cases and deaths due to colorectal cancer, according ...

Another study finds colonoscopy can save lives

June 19, 2013
(HealthDay)—There's more evidence that routine colonoscopy confers life-extending benefits.

Too many americans skipping colon cancer screening

March 2, 2012
(HealthDay) -- Approximately one in three U.S. adults between the ages of 50 and 75 who should be screened for colorectal cancer have not been, according to the American Society for Gastrointestinal Endoscopy.

Recommended for you

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Scientists block the siren call of two aggressive cancers

January 23, 2018
Aggressive cancers like glioblastoma and metastatic breast cancer have in common a siren call that beckons the bone marrow to send along whatever the tumors need to survive and thrive.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.